Barinthus Biotherapeutics (BRNS) EBIT (2020 - 2026)

Barinthus Biotherapeutics has reported EBIT for 7 years, with the latest figure at -$6.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 70.51% year-over-year to -$6.1 million; the trailing twelve-month figure through Mar 2026 stood at -$56.0 million (up 21.81% YoY), and the FY2025 full-year result was -$70.6 million, down 3.8% from the prior year.
• EBIT for Q1 2026 stood at -$6.1 million, up from -$11.6 million in the prior quarter.
• The five-year high for EBIT was $13.2 million in Q2 2022, with the low at -$26.3 million in Q2 2023.
• Historically, EBIT has averaged -$13.7 million across 5 years, with a median of -$16.9 million in 2024.
• Annual changes were most pronounced in 2022 — EBIT jumped 230.71% — and 2023, when it tumbled 3385.02%.
• Barinthus Biotherapeutics' EBIT stood at -$25.1 million in 2022, then grew by 20.34% to -$20.0 million in 2023, then fell by 17.02% to -$23.4 million in 2024, then surged by 50.56% to -$11.6 million in 2025, then soared by 47.47% to -$6.1 million in 2026.
• The last three EBIT figures came in at -$6.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$15.1 million (Q3 2025), per Business Quant data.